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IRSp53 coordinates AMPK and 14-3-3 signaling
to regulate filopodia dynamics and directed cell
migration
David J. Kast†,* and Roberto Dominguez*
Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104

ABSTRACT Filopodia are actin-filled membrane protrusions that play essential roles in cell
motility and cell–cell communication and act as precursors of dendritic spines. IRSp53 is an
essential regulator of filopodia formation, which couples Rho-GTPase signaling to actin cytoskeleton and membrane remodeling. IRSp53 has three major domains: an N-terminal inverseBAR (I-BAR) domain, a Cdc42- and SH3-binding CRIB-PR domain, and an SH3 domain that
binds downstream cytoskeletal effectors. Phosphorylation sites in the region between the
CRIB-PR and SH3 domains mediate the binding of 14-3-3. Yet the mechanism by which 14-3-3
regulates filopodia formation and dynamics and its role in cell migration are poorly
understood. Here, we show that phosphorylation-dependent inhibition of IRSp53 by 14-3-3
counters activation by Cdc42 and cytoskeletal effectors, resulting in down-regulation of
filopodia dynamics and cancer cell migration. In serum-starved cells, increased IRSp53
phosphorylation triggers 14-3-3 binding, which inhibits filopodia formation and dynamics,
irrespective of whether IRSp53 is activated by Cdc42 or downstream effectors (Eps8, Ena/
VASP). Pharmacological activation or inhibition of AMPK, respectively, increases or decreases
the phosphorylation of two of three sites in IRSp53 implicated in 14-3-3 binding. Mutating
these phosphorylation sites reverses 14-3-3-dependent inhibition of filopodia dynamics and
cancer cell chemotaxis.
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INTRODUCTION
Cell migration is an essential process in tissue and organ development, and it is also the source of pathological conditions such as
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inflammation and cancer metastasis (Friedl and Gilmour, 2009).
Migrating cells project filopodia, which are thin, rod-like membrane
protrusions that dynamically extend and retract as a result of the
polymerization/depolymerization of parallel bundles of actin
filaments in their interior (Mattila and Lappalainen, 2008; Yang and
Svitkina, 2011; Fischer et al., 2018). Filopodia act as sensory organs
of the cell, which in response to chemical gradients or tension
changes mediate the crosstalk of cells with their neighbors and the
environment (Chan and Odde, 2008; Jacquemet et al., 2015). As a
result, filopodia play a central role in cell migration and the establishment of cell polarity (Meyen et al., 2015). However, the mechanisms
by which cells regulate filopodia formation and dynamics in response
to signaling and mechanical cues are not fully understood.
IRSp53 (also known as BAIAP2) is a key regulator of filopodia formation and cell motility that couples Rho GTPase and kinase signaling pathways with actin cytoskeleton remodeling and membrane
dynamics (Miki et al., 2000; Krugmann et al., 2001; Disanza et al.,
2006, 2013; Disanza and Scita, 2008; Suetsugu et al., 2006; Goh
et al., 2012; Kast et al., 2014; Carman and Dominguez, 2018). IRSp53
plays essential roles in a number of developmental processes, such
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as eye lens formation (Chauhan et al., 2009), myoblast fusion (Segal
et al., 2016), and dendritic spine formation (Soltau et al., 2002, 2004).
Dysregulation of IRSp53 function is a contributing factor in tumorigenesis (Funato et al., 2004; Liu et al., 2010; Yan et al., 2017) and
several neurological disorders (Kang et al., 2016), including learning
defects (Bobsin and Kreienkamp, 2016), attention deficit disorder
(Ribases et al., 2009), autism spectrum disorder (Toma et al., 2011),
schizophrenia (Fromer et al., 2014), and Alzheimer’s disease (Wan
et al., 2013). The N-terminal ∼230 amino acids of IRSp53 consist of
an inverse BAR (I-BAR) domain, which mediates membrane binding/
deformation (Mattila et al., 2007) and antiparallel dimerization
(Millard et al., 2005; Lee et al., 2007b). Following the I-BAR domain,
IRSp53 has a Cdc42-binding motif that overlaps with a proline-rich
sequence and is thus referred to as the CRIB-PR domain. C-terminal
to the CRIB-PR domain, IRSp53 contains an SH3 domain, which mediates the interactions with a large number of cytoskeletal effectors,
including Eps8 (Funato et al., 2004; Disanza et al., 2006), Ena/
VASP (Krugmann et al., 2001; Disanza et al., 2013; Oikawa et al.,
2013), N-WASP (Lim et al., 2008), WAVE (Miki et al., 2000; Nakagawa
et al., 2003; Abou-Kheir et al., 2008), mDia (Fujiwara et al., 2000;
Goh et al., 2012), PSD-95 (Bockmann et al., 2002; Soltau et al., 2004;
Choi et al., 2005; Barilari and Dente, 2010) and Shank3 (Bockmann
et al., 2002; Soltau et al., 2002). In the inactive state, the SH3 domain
of IRSp53 binds intramolecularly to the CRIB-PR domain, partially
inhibiting IRSp53’s ability to induce plasma membrane remodeling in
cells (Kast et al., 2014). IRSp53 is activated by the binding of either
Cdc42 to the CRIB-PR domain and/or cytoskeletal effectors to the
SH3 domain (Kast et al., 2014), leading to increased formation of
membrane ruffles and filopodia-like protrusions (Krugmann et al.,
2001; Soltau et al., 2002; Disanza et al., 2006, 2013; Lim et al., 2008;
Kast et al., 2014).
The ∼80–amino acid region between the CRIB-PR and SH3 domains (residues 292–374) hosts multiple phosphorylation sites that
have been implicated in IRSp53 regulation (Heung et al., 2008;
Robens et al., 2010; Cohen et al., 2011; Kast and Dominguez, 2019).
In particular, three of these sites (T340, T360, and S366) have been
implicated in the binding of 14-3-3 (Robens et al., 2010; Cohen
et al., 2011; Kast and Dominguez, 2019). 14-3-3 proteins constitute
a conserved family of seven isoforms, denoted β, γ, ε, ζ, η, σ, and
θ (also called τ), that function as phospho-S/T adaptors to regulate
the activities of a large number of proteins in a phosphorylationdependent manner (Yaffe, 2002). Four 14-3-3 isoforms (γ, θ, ζ,
and σ) have been shown to bind to IRSp53 (Jin et al., 2004; Mackie
and Aitken, 2005; Robens et al., 2010; Cohen et al., 2011). Numerous ligands of 14-3-3 are proteins implicated in the regulation of cell
migration (Freeman and Morrison, 2011), whereas little is known
about the functional role of 14-3-3 binding to phosphorylated
IRSp53 (pIRSp53), or the kinases implicated in this regulatory mechanism. The one exception is the phosphorylation of IRSp53 residue
S366, known from chemical genetics screening to be mediated by
AMPK and AMPK-related kinases (Banko et al., 2011; Cohen et al.,
2011; Schaffer et al., 2015). Binding of 14-3-3 to this site leads to
loss of cell spreading and cell polarity (Cohen et al., 2011). While the
kinases that directly phosphorylate T340 and T360 are unknown, it
has been shown that 14-3-3 binding to these sites inhibits interactions with Cdc42 and cytoskeletal effectors (Robens et al., 2010;
Kast and Dominguez, 2019). Yet the functional consequences of the
interaction of 14-3-3 with pIRSp53 on the formation and dynamics
of filopodia and its effect on directed cell motility remain largely
unexplored.
Here, we show that 14-3-3 counters activation of phosphorylated
IRSp53 by Cdc42, Eps8 and VASP, resulting in impaired filopodia
1286 | D. J. Kast and R. Dominguez

formation and dynamics and cancer cell migration. We further show
that phosphorylation of two of the three sites that mediate the binding of 14-3-3 to IRSp53 (T360 and S366) increases with serum starvation or phenformin treatment and decreased with dorsomorphin
treatment, thus implicating AMPK in their phosphorylation. Collectively, the results demonstrate that IRSp53 is a chemotactic signal
transducer that in response to AMPK-dependent phosphorylation
and 14-3-3 binding down-regulates cytoskeleton and plasma membrane remodeling to inhibit cell motility.

RESULTS
14-3-3 inhibits IRSp53- and Cdc42-dependent
filopodia dynamics
Phosphorylation of IRSp53 has been shown to trigger its interaction
with 14-3-3 (Jin et al., 2004; Mackie and Aitken, 2005; Robens et al.,
2010; Cohen et al., 2011; Kast and Dominguez, 2019). However, it
remains to be demonstrated whether this interaction regulates the
activity of IRSp53, and specifically its role in filopodia formation and
cell migration activated by interactions with Cdc42 through its CRIBPR domain or downstream cytoskeletal effectors (such as Eps8 and
VASP) through its SH3 domain. We used spinning-disk confocal microscopy to determine the density, length and growth rate of filopodia-like structures (FLS) in live COS-7 cells expressing IRSp53-GFP,
RFP-Cdc42 (constitutively active mutant, G12V) and mTagBFP2-143-3θ (hereafter referred to as 14-3-3) individually or together (Figure
1 and Supplemental Figure S1). In these experiments, cells were
serum-starved, which we have found enhances IRSp53 phosphorylation at 14-3-3 binding sites (Kast and Dominguez, 2019). Because
the range of cellular protrusions observed was morphologically diverse, we define FLS as nontapered dynamic protrusions, 0.2–0.5 μm
in width and extending at least 0.5 μm from the cell periphery.
The density, length and growth rate of FLS was similar for cells
expressing IRSp53, Cdc42 or 14-3-3 individually (Figure 1, A and E,
and Supplemental Movie S1A), albeit the number of FLS formed in
cells expressing these proteins was greater than in untransfected
cells (Supplemental Figure S1, B and C). As previously described
(Kast et al., 2014), the majority to FLS in IRSp53-expressing cells
were filled with actin (Supplemental Figure S1B). When expressed
alone, IRSp53 was mainly found at the plasma membrane, which is
likely due to its affinity for PI(3,4)P2 and PI(4,5)P2 (Mattila et al.,
2007), which are naturally abundant in the plasma membrane. In
contrast, Cdc42 and 14-3-3 displayed mostly a diffused localization, with some accumulation at dynamic plasma membrane ruffles.
Coexpression of IRSp53 and Cdc42 produced many, long, and
highly dynamic FLS (Figure 1, B and E, and Supplemental Movie
S1B), consistent with previous observations (Krugmann et al., 2001;
Disanza et al., 2006, 2013; Lim et al., 2008; Kast et al., 2014).
IRSp53 and Cdc42 colocalized throughout the cell, and were specifically enriched in FLS. In contrast, coexpression of IRSp53 and
14-3-3 did not significantly change the density of FLS compared
with cells expressing these two proteins individually, but did produce a modest reduction in both the length and growth rate of FLS
(Figure 1, C and E, and Supplemental Movie S1C). Interestingly,
14-3-3 was less diffused in these cells than when expressed alone
and often colocalized with IRSp53 to dynamic membrane ruffles at
the cell periphery (Supplemental Movie S1C). Compared to cells
coexpressing IRSp53 and Cdc42, the additional expression of 143-3 markedly reduced the density, mean length and growth rate of
FLS (Figure 1, D and E, and Supplemental Movie S1D) and this inhibition was significantly more pronounced in serum-starved than
in fed cells (Supplemental Figure S1D). Membrane ruffles were
rarely observed in cells coexpressing the three proteins, and while
Molecular Biology of the Cell

FIGURE 1: 14-3-3 inhibits IRSp53- and Cdc42-induced FLS in live cells. (A) COS-7 cells individually expressing IRSp53GFP, RFP-Cdc42 or mTagBFP2-14-3-3 (as indicated). Scale bars throughout this figure represent 10 and 5 μm in
whole-cell and inset images, respectively. (B–D) COS-7 cells coexpressing IRSp53-GFP with RFP-Cdc42 or
mTagBFP2-14-3-3. Shown on the right are the average fluorescence intensities from 10 line scans across the cell edge
(as exemplified by dashed lines in the insets) and representative time series of growing FLS (scale bar = 5 μm). Arrows
point to examples of IRSp53, Cdc42 and 14-3-3 localization to cell protrusions. (E) Quantification of the density, length
and growth rate of FLS. The statistical significance of the measurements was determined using the Mann–Whitney rank
sum test, based on the indicated number of observations (n) recorded from 12–14 cells and two independent
transfections (n.s., nonsignificant; **p < 0.01; ****p < 0.0001).

IRSp53 and 14-3-3 colocalized along FLS, Cdc42 was mostly excluded from cell protrusions (Figure 1D, insets). In growing protrusions, 14-3-3 appeared to trail IRSp53 (Figure 1D, FLS insets, and
Volume 30 May 15, 2019

Supplemental Movie S1D). Together, these results suggest that 143-3 negatively regulates IRSp53- and Cdc42-dependent FLS formation and dynamics, and that colocalization of IRSp53 and 14-3-3 at
IRSp53 and 14-3-3 regulate cell motility
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cell protrusions displaces Cdc42, consistent with these two proteins
binding competitively to IRSp53.

binding of Cdc42 to the CRIB-PR domain or cytoskeletal effectors
to the SH3 domain.

14-3-3 inhibits IRSp53- and effector-dependent
filopodia dynamics

AMPK-dependent IRSp53 phosphorylation inhibits
filopodia dynamics

Downstream cytoskeletal effectors that bind to the SH3 domain can
also activate filopodia formation by IRSp53 (Disanza et al., 2006,
2013; Kast et al., 2014). Thus, we asked whether 14-3-3 also inhibits
effector-induced FLS formation and dynamics. To address this
question, we studied two well-characterized downstream effectors
of IRSp53: the oncoprotein Eps8 (Funato et al., 2004; Disanza et al.,
2006; Liu et al., 2010; Robens et al., 2010; Kast et al., 2014) and the
actin filament elongation factor VASP (Vaggi et al., 2011; Disanza
et al., 2013).
Similar to Cdc42, expression of GFP-Eps8 alone had little effect
on FLS number, size, or dynamics (Figure 2, A and E, and Supplemental Movie S2A). However, distinct from the diffused localization
of Cdc42 (Figure 1A), Eps8 was enriched near the cell periphery, and
despite relatively low ectopic expression levels (Supplemental
Figure S2), it promoted the formation of microspikes extending
<0.5 μm from the edge of the cell (arrows in Figure 2A, inset). Similar
to Cdc42 (Figure 1B), coexpression of Eps8 and IRSp53 dramatically
increased the density, length and growth rate of FLS (Figure 2, B and
E, and Supplemental Movie S2B), consistent with previous observations (Disanza et al., 2006; Kast et al., 2014). In these cells, the cytosolic distribution of IRSp53 and Eps8 was virtually eliminated; both
proteins colocalized along the length of FLS and on patches at the
plasma membrane. Coexpression of Eps8 and 14-3-3 did not have
any significant effect on FLS behavior (Figure 2, C and E, and Supplemental Movie S2C). These two proteins appeared mostly segregated, with Eps8 restricted to the cell periphery and 14-3-3 diffused
throughout the cytosol. Compared to cells coexpressing IRSp53
and Eps8, the additional expression of 14-3-3 had a dramatic inhibitory effect on the length and growth rate of FLS (Figure 2, D and E,
and Supplemental Movie S2D), analogous to the effect of 14-3-3 on
FLS formed by IRSp53 and Cdc42 (Figure 1D).
Similar results were obtained in serum-starved COS-7 cells expressing GFP-VASP (Figure 2, F–J, and Supplemental Movie S2,
E–H), another effector of IRSp53 that drives actin filament elongation when clustered by IRSp53 at the cell periphery (Disanza et al.,
2013). When expressed alone, VASP localized mainly to focal adhesions and near the cell periphery (arrows in Figure 2F, inset). Although GFP-VASP was expressed at approximately ninefold higher
levels than endogenous VASP (Supplemental Figure S2), it had no
significant effect on the behavior of cell protrusions (Figure 2, F and
J, and Supplemental Movie S2E). The coexpression of VASP with
IRSp53 dramatically increased the number and dynamics of FLS
(Figure 2, G and J, and Supplemental Movie S2F), consistent with
previous observations (Disanza et al., 2013). However, VASP’s coexpression with 14-3-3 had no apparent effect on the behavior or
appearance of FLS compared with cells expressing VASP alone
(Figure 2, H and J, and Supplemental Movie S2G). In these cells,
14-3-3 was diffusely localized and mostly excluded from VASP clusters (arrows in Figure 2H, insets). The coexpression of 14-3-3 with
VASP and IRSp53 dramatically reduced the number and growth
rate of FLS, although it did not significantly change their average
length (Figure 2, I and J, and Supplemental Movie S2H). In this
case, 14-3-3 accumulated in patches where VASP and IRSp53 also
colocalized (Figure 2I, arrows in insets). Together, these observations suggest that 14-3-3-dependent inhibition of filopodia formation and growth dynamics involves a direct interaction with IRSp53
and occurs independent of whether IRSp53 is activated by the

Based on phosphoproteomic studies compiled in PhosphoSitePlus
(Hornbeck et al., 2015), IRSp53 is most frequently phosphorylated in
the S/T-rich region that links the CRIB-PR and SH3 domains. 14-3-3
binding to this region inhibits the binding of Cdc42 to the CRIB-PR
and cytoskeletal effectors to the SH3 domain (Robens et al., 2010;
Cohen et al., 2011; Kast and Dominguez, 2019). Consistently, phosphorylation of IRSp53 at T340 and T360, possibly by a kinase downstream of GSK3β although not GSK3β itself (Robens et al., 2010),
and S366 by AMPK (Banko et al., 2011; Schaffer et al., 2015) or the
AMPK-related kinases MARK1 (Goodwin et al., 2014) and MARK2
(Cohen et al., 2011), have been linked to 14-3-3 binding. While
these studies point to different kinases and phosphorylation sites, in
a recent study we show that 14-3-3 binds to two pairs of phosphorylation sites that share one site in common (pT340/pT360 and pT340/
pS366), thus reconciling previous findings (Kast and Dominguez,
2019). However, disagreement persists about the specific kinase(s)
responsible for IRSp53 phosphorylation in connection with 14-3-3
binding, albeit AMPK-related kinases emerge as the most likely candidate (Banko et al., 2011; Cohen et al., 2011; Goodwin et al., 2014;
Schaffer et al., 2015). Consistent with these studies, we have found
that serum starvation, a condition that enhances AMPK-dependent
phosphorylation (Pirkmajer and Chibalin, 2011), increases the
amount of 14-3-3 that coimmunoprecipitates with IRSp53-FLAG
from cells (Kast and Dominguez, 2019).
Here, we tested the role of AMPK-related kinases on 14-3-3-dependent regulation of IRSp53. In control experiments, 2-h serum
starvation increased the phosphorylation of acetyl-CoA carboxylase
(ACC), a known AMPK substrate (Munday et al., 1988), and ACC
phosphorylation was reduced by treatment with dorsomorphin (also
known as compound C), a specific inhibitor of AMPK-related kinases
(Zhou et al., 2001) (Figure 3A). Neither serum starvation nor dorsomorphin treatment affected the expression levels of IRSp53 or 143-3 (Figure 3B). Yet, analogous to ACC, serum starvation led to an
approximately threefold increase in the total amount of 14-3-3 that
coimmunoprecipitates with IRSp53-FLAG, and this effect was
strongly attenuated by dorsomorphin treatment (Figure 3B). Furthermore, dorsomorphin treatment dramatically reduced the phosphorylation of IRSp53 at residues T360 and S366, as revealed by
phosphopeptide fingerprinting using mass spectrometry (Figure 3C
and Supplemental Tables S1 and S2). Consistent with these results,
IRSp53-expressing cells treated with dorsomorphin displayed
increased FLS formation (Figure 3D and Supplemental Movie S3),
presumably due to reduced binding and inhibition by endogenous
14-3-3 that is expressed at high levels (Sluchanko and Gusev, 2017).
Furthermore, insulin treatment postserum starvation, a condition
known to increase filopodia formation (Heung et al., 2008), significantly reduced the amount of 14-3-3 that coimmunoprecipitates
with IRSp53 (Supplemental Figure S3). Conversely, treatment of
cells with phenformin, an AMPK-specific activator (Hawley et al.,
2003), led to a significant increase in the association of 14-3-3 with
IRSp53 (Figure 3, E and F). Phenformin specifically activates AMPK,
and not other AMPK-related kinases (Lizcano et al., 2004; Sakamoto
et al., 2004). Phenformin-dependent activation depends on the
phosphorylation of the AMPK catalytic (α) subunit at residue T172,
which is basally phosphorylated by calmodulin-dependent protein
kinase kinase (CAMKK) (Vincent et al., 2015). Therefore, to monitor
the activation of AMPK in fed HEK293T cells, we examined the
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FIGURE 2: 14-3-3 Inhibits IRSp53, EPS8, and VASP-induced FLS in live cells. (A–D) Serum-starved COS-7 cells
coexpressing GFP-Eps8 with IRSp53-mTagBFP2 or mCherry-14-3-3 (individually or together). Arrows point to examples
of IRSp53, Eps8, and 14-3-3 localization to cell protrusions. Scale bars throughout this figure represent 10 and 5 μm in
whole-cell and inset images, respectively. (E) Quantification of the density, length, and growth rate of FLS. The statistical
significance of the measurements was determined using the Mann–Whitney rank sum test, based on the indicated
number of observations (n) reordered from 7–10 cells and two independent transfections (n.s., nonsignificant;
**p < 0.01; ****p < 0.0001). (F–I) Serum-starved COS-7 cells coexpressing GFP-VASP with IRSp53-mTagBFP2 or
mCherry-14-3-3 (individually or together). Arrows point to examples of VASP, IRSp53 and 14-3-3 localization. Notice that
the density of 14-3-3 drops in VASP-enriched areas (H), whereas 14-3-3 is enriched in areas positive for both IRSp53 and
VASP (I). (J) Quantification of the density, length, and growth rate of FLS. The statistical significance of the
measurements was determined using the Mann–Whitney rank sum test, based on the indicated number of observations
(n) reordered from 7–10 cells and two independent transfections (n.s., nonsignificant; ****p < 0.0001).

extent of T172 phosphorylation in response to phenformin treatment after reducing the basal phosphorylation of AMPK by treatment with STO-609, a CAMKK inhibitor (Tokumitsu et al., 2002). On
STO-609 treatment, the addition of 0.5 or 1.0 mM phenformin
Volume 30 May 15, 2019

greatly enhanced the phosphorylation of T172 (Figure 3E), whereas
the expression levels of IRSp53 and 14-3-3 appeared unaffected
(Figure 3F). Importantly, phenformin treatment led to a 7- to 11-fold
increase in the total amount of 14-3-3 coimmunoprecipitating with
IRSp53 and 14-3-3 regulate cell motility
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FIGURE 3: AMPK-mediated phosphorylation controls the binding of 14-3-3 to IRSp53. (A) Effect of serum starvation
and dorsomorphin-dependent inhibition of AMPK-related kinases on the phosphorylation of the canonical AMPK
substrate acetyl-CoA carboxylase (ACC) in HEK293T cells. (B) Amount of 14-3-3 that coimmunoprecipitates with
IRSp53-FLAG from HEK293T cells. Note that neither serum starvation nor dorsomorphin treatment affects the
expression of endogenous 14-3-3, whereas starvation increases and dorsomorphin decreases the amount of 14-3-3 that
coimmunoprecipitates with IRSp53-FLAG. Abundance is reported relative to fed cells expressing IRSp53-FLAG.
(C) Relative change in the fraction of phosphorylated IRSp53 peptides detected by tandem MS/MS in DMSO-treated vs.
5 μM dorsomorphin-treated starved cells. (D) COS-7 cell expressing IRSp53-GFP treated with 5 μM dorsomorphin. Scale
bars represent 10 and 5 μm in whole-cell and inset images, respectively. (E) Effect of phenformin treatment on the
phosphorylation of residue T172 of the catalytic subunit of AMPK (kinase activation) in HEK293T cells. Cells were
pretreated with the Ca2+-CAMKK inhibitor STO-609 to suppress basal phosphorylation of AMPK before treatment with
the indicated concentrations of phenformin. (F) Amount of 14-3-3 that coimmunoprecipitates with IRSp53-FLAG from
HEK293T cells treated with phenformin. Note that neither STO-609 nor phenformin treatment affect the expression of
IRSp53-FLAG or endogenous 14-3-3, whereas phenformin dramatically increases the amount of 14-3-3 that
coimmunoprecipitates with IRSp53-FLAG. Abundance is reported relative to untreated fed cells expressing IRSp53FLAG. Throughout this figure, error bars are ± SD from three independent experiments. The statistical significance of all
the measurements was determined using an unpaired t test based on three independent experiments (n.s.,
nonsignificant; *p < 0.05, **p < 0.01, ***p < 0.001).

IRSp53-FLAG (Figure 3F). Combined, these results support the notion that phosphorylation of at least two of the three 14-3-3 binding
sites in IRSp53 depends either directly or indirectly on the activity of
AMPK.

Disrupting 14-3-3 binding to IRSp53 leads
to aberrant FLS formation
To specifically test the role of IRSp53 phosphorylation and 14-3-3
binding on the inhibition of FLS formation and dynamics, we generated a mutant in which the three phosphorylation sites implicated in
14-3-3 binding, located between the CRIB-PR and SH3 domains
(Robens et al., 2010; Cohen et al., 2011; Kast and Dominguez,
2019), were simultaneously mutated to alanine (Figure 4A). For consistency with our recent study (Kast and Dominguez, 2019), we call
this mutant M234 (IRSp53 mutant T340A/T360A/S366A). When expressed alone and approximately to the same extent as WT IRSp53
(compare Supplemental Figures S1A and S4A), M234 significantly
1290 | D. J. Kast and R. Dominguez

increased the number of FLS (Figure 4, B and F, and Supplemental
Movie S3A), potentially reflecting the lack of IRSp53 inhibition by
endogenous 14-3-3. Importantly, FLS formed with mutant M234
were mostly filled with actin (Supplemental Figure S4B) but were
frequently branched, although the cause of this phenotype is unclear (arrows in Figure 4B, inset). Coexpression of M234 with Cdc42
further increased the number, length, and growth rate of FLS (Supplemental Figure S4C and Supplemental Movie S3C), whereas coexpression of M234 with 14-3-3 did not appreciably inhibit FLS formation (Supplemental Figure S4D and Supplemental Movie S3D).
The protrusions formed under these conditions, however, could not
be reliably quantified, as they were highly branched and curved.
Compared to WT IRSp53, cells coexpressing M234, Cdc42, and
14-3-3 displayed a markedly increased number of FLS, which were
also longer and more dynamic (Figure 4, C and F, and Supplemental
Movie S3E). 14-3-3 was largely excluded from these protrusions
(Figure 4, C and D), which is consistent with the lack of binding to
Molecular Biology of the Cell

FIGURE 4: Phosphoinhibitory mutations in IRSp53 abrogate 14-3-3-dependent inhibition of FLS dynamics. (A) Domain
diagram of IRSp53 showing the three residues that on phosphorylation mediate the binding of 14-3-3 and which were
mutated to alanine in mutant M234 (B) COS-7 cell expressing M234-GFP (IRSp53 mutant T340A/T360A/S366A). Scale
bars throughout this figure represent 10 and 5 μm in whole-cell and inset images, respectively. (C) COS-7 cell expressing
M234-GFP, RFP-Cdc42, and mTagBFP2-14-3-3. (D) Average fluorescence intensities from 10 line scans across the cell
edge (as exemplified by dashed lines in the insets in C) and a representative time series of a growing FLS (indicated by
arrows). Scale bar represents 5 μm. (E) COS-7 cell expressing M234-GFP, mCherry-Eps8 and mTagBFP2-14-3-3.
(F) Quantification of the density, length, and growth rate of FLS. The statistical significance of the measurements was
determined using the Mann–Whitney rank sum test, based on the indicated number of observations (n) recorded from
7–10 cells and two independent transfections (n.s., nonsignificant; *p < 0.05; **p < 0.01; ****p < 0.0001).

IRSp53. In support of this interpretation, FLS from cells expressing
M234 were not as sensitive to serum starvation as those from cells
expressing IRSp53 (compare Supplemental Figures S1D and S4E).
When coexpressed with Eps8 and 14-3-3, M234 also produced
more FLS than WT IRSp53, and these protrusions were significantly
longer and somewhat more dynamic (Figure 4, E and F, and Supplemental Movie S3F). 14-3-3 was also largely absent from FLS in these
cells. Interestingly, however, both WT IRSp53 and M234 produced
more dynamic FLS when activated by Cdc42 than by Eps8 (Figure
4F), suggesting that Cdc42 plays roles in both FLS initiation and
dynamics, whereas Eps8 only impacts initiation. These results allow
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us to conclude that the sole mutation of three S/T residues implicated in 14-3-3 binding in IRSp53 leads to dramatic effects in FLS
formation and dynamics, likely due to the lack of inhibition by
14-3-3.

14-3-3 binding to IRSp53 inhibits cancer cell chemotaxis
Dynamic filopodia are required to establish cell polarity and drivedirected cell migration in vivo (Meyen et al., 2015). Since 14-3-3
inhibits IRSp53-dependent FLS formation and dynamics, we asked
whether it also regulates cell motility and polarity through phosphorylation-dependent interaction with IRSp53. We analyzed the
IRSp53 and 14-3-3 regulate cell motility
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FIGURE 5: 14-3-3 binding to IRSp53 inhibits cancer cell chemotaxis. (A, B) Serum-starved fibrosarcoma HT-1080 cells
expressing RFP-Cdc42, mTagBFP2-14-3-3, and IRSp53-GFP (or M234-GFP). Scale bars represent 10 and 5 μm in
whole-cell and inset images, respectively. (C) Quantification of the density, length, and growth rate of FLS. The statistical
significance of the measurements was determined using the Mann–Whitney rank sum test, based on the indicated
number of observations (n) reordered from six cells and two independent transfections (**p < 0.01; ****p < 0.0001).
(D) Quantification of the fraction of HT-1080 cells expressing RFP-Cdc42, mTagBFP2-14-3-3, and either IRSp53-GFP
(green traces) or M234-GFP (blue traces) that migrate from the top plate (0.5% FBS) to the bottom plate (0.5–20% FBS)
of a 96-well IncuCyte chemotaxis system as a function chemoattractant concentration. Chemotaxis plates were
calibrated by quantifying the time at which the highest fraction of control cells (untransfected cells, black lines) had
migrated to the bottom plate, corresponding to 33 h for IRSp53 and 42 h for M234. (E) Statistical analyses of cell
chemotaxis were performed at the optimal chemoattractant concentration of 10% FBS (determined from D). Error bars
are ± SD from two independent experiments per expression condition, each consisting of three replicas. The statistical
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chemotactic migration of human fibrosarcoma HT-1080 cells as a
function of IRSp53 or M234 coexpression with Cdc42 and 14-3-3.
Unlike COS-7 cells (Figure 1, D and E), HT-1080 cells coexpressing
IRSp53, Cdc42, and 14-3-3 produced a small number of FLS, and
these FLS were typically short and had a low growth rate (Figure 5,
A and C, and Supplemental Movie S4A). In contrast, a large number
of dynamic FLS were observed in cells coexpressing M234, Cdc42,
and 14-3-3 (Figure 5, B and C, and Supplemental Movie S4B). Similar to COS-7 cells (Figure 4, B–D), M234 localized mainly to the
plasma membrane and FLS, and Cdc42 tended to colocalize with
M234, whereas 14-3-3 was mostly absent from FLS (Figure 5B and
Supplemental Movie S4B).
We tracked the movement of HT-1080 cells expressing WT
IRSp53 and M234 using a 96-well chemotaxis plate setup, where
cells in the upper chamber migrate toward a lower reservoir containing the chemoattractant. Over a range of chemoattractant concentrations (0.5–20% fetal bovine serum [FBS]), cells expressing either
IRSp53 or M234 performed chemotaxis less efficiently than untransfected cells (Figure 5D). For both transfected and untransfected
cells, the fraction of migrated cells peaked at 10% chemoattractant,
which was selected as the optimal concentration for statistical analysis (Figure 5E). Cells expressing WT IRSp53 displayed lower overall
chemotaxis efficiency than cells expressing M234, particularly at
lower chemoattractant concentrations (≤10%). However, the difference between IRSp53 and M234 became far more pronounced
when coexpressed with Cdc42 and 14-3-3, which had no effect on
the migration of M234-expressing cells but severely reduced the
migration of IRSp53-expressing cells (Figure 5, D and E). These results suggest that phosphorylation-dependent inhibition of IRSp53
by 14-3-3 regulates polarized cell migration.

DISCUSSION
This study establishes IRSp53 as a chemotactic signal transducer
that in response to AMPK-dependent phosphorylation (and likely
phosphorylation by other kinases) binds 14-3-3, which in turn downregulates cytoskeleton and plasma membrane remodeling, filopodia formation, and cell motility (Figure 5F). Owing to its unique
multidomain architecture, IRSp53 acts as a signaling hub, capable of
integrating activatory (GTP-Cdc42, membrane curvature and phospholipids, downstream cytoskeleton effectors) and inhibitory (intramolecular CRIB-PR/SH3 interaction, phosphorylation, and 14-3-3
binding) inputs. Cytoskeleton and membrane remodeling effects
are further enhanced through the formation of two-dimensional
coats at the membrane via lateral oligomerization, as observed for
IRSp53 as well as other members of the I-BAR protein family (Mattila
et al., 2007; Saarikangas et al., 2009; Pykalainen et al., 2011; Prevost
et al., 2015; Carman and Dominguez, 2018).
The live-cell studies described here show that 14-3-3 inhibits
IRSp53-dependent FLS formation and dynamics irrespective of
whether it is activated by interaction with Cdc42 via its CRIB-PR domain or with cytoskeletal effectors such as Eps8 and VASP via its
SH3 domain (Figures 1 and 2). Phosphoproteomics and coimmuno-

precipitation of 14-3-3 from serum-starved, dorsomorphin-, or
phenformin-treated cells clearly implicate AMPK (and possibly
AMPK-related kinases) in the phosphorylation of at least two of the
sites responsible for 14-3-3 binding (T360 and S366) (Figure 3). Of
these, S366 is known to be directly phosphorylated by AMPK and
AMPK-related kinases from chemical genetics screening studies
(Banko et al., 2011; Cohen et al., 2011; Schaffer et al., 2015),
whereas the effect of AMPK on the phosphorylation of T360 could
be indirect. We further show that dorsomorphin treatment leads to
a dramatic increase in the number of FLS (Figure 3D and Supplemental Movie S3B), further implicating AMPK in the regulation of
cell protrusion formation and consistent with its role in the control of
actin dynamics (Moser et al., 2010), cell polarity (Lee et al., 2007a),
and cell motility (Hurtado de Llera et al., 2012; Yan et al., 2015;
Aparicio et al., 2016; Kumar et al., 2018). Whereas the kinase(s)
implicated in the phosphorylation of T340 is still unknown, one thing
seems clear – different kinases converge on IRSp53 to control 143-3 binding, offering alternative routes of regulation.
Perhaps more striking is the explosive increase in FLS formation
observed with mutant M234 when expressed alone or in conjunction with Cdc42 (or Eps8) and 14-3-3 (Figure 4 and Supplemental
Figure S4). Of note, only three S/T residues of the 521 residues of
IRSp53 were substituted by alanine in this mutant (T340A, T360A,
and S366A). These three mutations are unlikely to affect folding
since they fall within the 83-aa region between the CRIB-PR and
SH3 domains, which is predicted unstructured with three types of
amino acids (S/T/P) accounting for 36% of the sequence. These
observations highlight at least three points: 1) the intramolecular
autoinhibitory interaction between the CRIB-PR and SH3 domains
(Krugmann et al., 2001; Lim et al., 2008; Kast et al., 2014) is insufficient to maintain IRSp53 in a fully inactive state. This likely explains
why the autoinhibited conformation can be competitively reversed
in vitro and in cells by interactions with the plasma membrane,
Cdc42, and cytoskeletal effectors (Kast et al., 2014). 2) Complete
IRSp53 inhibition depends on phosphorylation-dependent interaction with 14-3-3. 3) It conclusively demonstrates that other than
through membrane binding, IRSp53 contributes to membrane remodeling through its ability to recruit cytoskeletal effectors. Indeed,
when expressed alone, the I-BAR domain of IRSp53 increases the
number of FLS to approximately the same extent as full-length
IRSp53 activated by Cdc42, but this effect is through membrane
deformation alone (decoupled from cytoskeleton assembly) and, as
a result, some of these filopodia are not actin-filled (Kast et al.,
2014). In contrast, M234 produces many more filopodia than fulllength IRSp53 when coexpressed with Cdc42 (or Eps8) and 14-3-3,
and these protrusions are filled with actin to a similar extent as for
WT IRSp53 (Supplemental Figure S4B). Such a dramatic increase in
protrusion formation can be explained only by the combined contribution of IRSp53’s other domains, including recruitment to Cdc42
patches at the membrane via its CRIB-PR domain and recruitment of
downstream actin assembly factors via its SH3 domain. Curiously,
the FLS formed by M234 are often branched and much longer than

significance of the measurements was determined using an unpaired t test based on three independent experiments
(n.s., nonsignificant; **p < 0.01; ***p < 0.001). (F) The role of IRSp53 in cell protrusion dynamics. IRSp53 exists in two
states: active (Cdc42-, membrane-, and cytoskeletal effector-bound) and inactive (autoinhibited through intramolecular
interaction of the CRIB-PR and SH3 domains and additionally locked on phosphorylation-dependent binding of 14-3-3).
AMPK is directly and/or indirectly responsible for the phosphorylation of two of the three 14-3-3 binding sites (T360 and
S366). In the active state, IRSp53 forms coats at the membrane, which dictates the curvature of the membrane (Carman
and Dominguez, 2018), and recruits cytoskeletal proteins that promote actin assembly to induce the formation of
dynamic cell protrusions. Cell protrusion formation is inhibited in the inactive state.
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with WT IRSp53 (Figure 4B and Supplemental Figure S4C). The reason for this phenotype is unclear, but it could be due to increased
accumulation of unregulated M234 along the plasma membrane
(Kast and Dominguez, 2019).
The results also provide additional insights into previous observations that the lifetime of FLS increases when two of the three 143-3 binding sites are removed in IRSp53 (Robens et al., 2010). Our
observed increase in the length of FLS on expression of M234 is in
principle consistent with longer FLS lifetimes. However, we also observed that the growth rate of FLS was similar for IRSp53- and M234expressing cells, which suggests that the longer lifetimes of FLS may
be due to a deficiency with the removal of M234 from the plasma
membrane by 14-3-3. Consistent with this interpretation, IRSp53
becomes more abundant in the cytosol with serum starvation,
whereas M234 remains enriched at plasma membrane (Kast and
Dominguez, 2019). These results suggest that 14-3-3 enhances filopodia dynamics by controlling the abundance of IRSp53 at the
plasma membrane.
We also show that 14-3-3 inhibits chemotaxis of IRSp53-expressing cancer cells, but has no effect on those cells expressing the mutant M234 (Figure 5). 14-3-3 proteins are a conserved family of
phospho-S/T adaptors, known primarily for their roles in the control
of cell-cycle progression and apoptosis (Gardino and Yaffe, 2011)
and the regulation of cell metabolism (Kleppe et al., 2011). Yet 143-3 also interacts with several cytoskeletal proteins, and like AMPK
(see above) has been implicated in the regulation of actin cytoskeleton and membrane dynamics (Gohla and Bokoch, 2002; Jin et al.,
2004; Rosenberg et al., 2008; Robens et al., 2010; Cohen et al.,
2011; Freeman and Morrison, 2011; Boudreau et al., 2013) and in
countless examples of cell migration regulation (Toyo-oka et al.,
2003; Preisinger et al., 2004; Tak et al., 2007; Yu et al., 2008; O’Toole
et al., 2011; Goc et al., 2012; Tsigkari et al., 2012; Wu et al., 2018).
Whether and how 14-3-3 and AMPK work together in these processes is unknown, since in most cases the kinases that phosphorylate 14-3-3 binding sites are unknown. This study provides strong
support for a cellular mechanism whereby 14-3-3 and AMPK (or
AMPK-related kinases) work hand-in-hand to control cell morphology and motility, using IRSp53 as an intermediate.

MATERIALS AND METHODS
Antibodies
Mouse monoclonal anti-IRSp53 (catalogue number: sc-136470;
1:500 dilution), mouse monoclonal anti–pan-14-3-3 (catalogue
number: sc-133233; 1:500 dilution), mouse monoclonal anti–β-actin
(catalogue number: sc-47778; 1:1000 dilution), and mouse monoclonal anti-GAPDH (catalogue number: sc-32223; 1:1000 dilution) were
purchased from Santa Cruz Biotechnology (Dallas, TX). Rabbit monoclonal anti-Cdc42 (catalogue number: 2462S; 1:1000 dilution), rabbit
monoclonal anti-Eps8 (catalogue number: 43114S; 1:1000 dilution),
rabbit monoclonal anti-VASP (catalogue number: 2795S; 1:1000 dilution), rabbit monoclonal anti-AMPKα1 (catalogue number: 2795S;
1:1000 dilution), rabbit monoclonal anti–phospho-AMPKα1 (T172)
(catalogue number: 2535S; 1:1000 dilution), rabbit monoclonal antiACC (phospho-acetyl-CoA carboxylase; catalogue number: 11818S;
1:1000 dilution), and horseradish peroxidase (HRP)-linked antimouse and anti-rabbit immunoglobulin G secondary antibodies
(catalogue numbers: 7076S and 7074S; 1:5000 dilution) were
purchased from Cell Signaling Technology (Danvers, MA).

Protein cloning, expression, and purification
Mammalian cell expression constructs. Full-length human IRSp53
(UniProt: Q9UQB8, isoform 4) was cloned into vectors pEGFP-N1
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and mTagBFP2-N1. For Co-IPs and protein purification, IRSp53 was
PCR-extended to include a C-terminal FLAG-tag and cloned into
vector pEGFP-C1 using restriction sites NheI and SalI. IRSp53 mutations T340A, T360A, and S366A were introduced using the QuickChange II XL mutagenesis kit (Agilent Technologies, Santa Clara, CA;
catalogue number: 200521). Full-length human Eps8 (UniProt:
Q12929) and human 14-3-3θ (UniProt: P27348) were cloned into
vectors mTagBFP2-C1, pEGFP-C1, and mCherry-C1 for live-cell imaging. Both human RFP-Cdc42 (constitutively active mutant G12V)
and human GFP-VASP were gifts from Tatyana Svitkina (University of
Pennsylvania). Constructs were generated using the primers and/or
oligos reported in Supplemental Table S3, and inserted genes in all
expression constructs were fully sequenced (Supplemental Table S4).
Mammalian cell protein expression and purification. IRSp53FLAG for pull-down studies was expressed in HEK293 cells grown to
∼40% confluence in 15-cm plates, transiently transfected with 10 μg
plasmid DNA in 30 μl of a 1 mg ml–1 polyethylenimine solution
(Polysciences, Warrington, PA; catalogue number: 23966). After 48 h
expression, IRSp53 phosphorylation was increased by serum-
depriving cells for 2 h (see below). Cells were then washed and incubated in phosphate-buffered saline (PBS) with the addition of 0.1 μM
Calyculin-A (Cell Signaling Technology, Danvers, MA; catalogue
number: 9902) and 1× Halt Phosphatase Inhibitor Cocktail (Thermo
Fisher Scientific, Waltham, MA; catalogue number: 87796) for 15 min
at 37°C. Cells were harvested, pelleted, and resuspended in lysis buffer composed of PBS supplemented with 1 mM EDTA, 5% glycerol,
1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 μM
Calyculin A, 1× cOmplete protease inhibitor cocktail (MilliporeSigma,
St. Louis, MO; catalogue number: 11697498001), and 1× Halt Phosphatase Inhibitor Cocktail. Cells were then incubated in lysis buffer on
ice for 30 min and freeze–thawed three times. Insoluble cellular components and nuclei were removed by centrifugation at 12,000 × g for
10 min. Clarified lysates were incubated with 25 μl anti-FLAG antibody conjugated to magnetic beads (MilliporeSigma; catalogue
number: M8823-1ML) for 2 h at 4°C and washed three times with
250 μl of lysis buffer (without Triton X-100). IRSp53 was eluted with
50 μl wash buffer supplemented with 300 mM NaCl and 0.5 mg ml–1
3xFLAG peptide (Bimake, Jupiter, FL; catalogue number: B23112).
Proteins were visualized by Western blot using Immobilon-P polyvinylidene difluoride (PVDF) membranes (MilliporeSigma; catalogue
number: IPVH00010). The relative abundance of proteins was determined by densitometry analysis using the program Fiji (https://
imagej.net/Fiji). All blots presented in the figures were prepared from
the unmodified blots shown in Supplemental Figure S5.

Cell lines, media, transfections, activators, and inhibitors
HEK293T cells (HEK293T/17; catalogue number: CRL-11268) and
COS-7 cell (catalogue number: CRL-1651) were purchased from the
American Type Culture Collection (Manassas, VA). HT-1080 cells were
from Essen BioScience (Ann Arbor, MI). Cells were authenticated and
verified to be free of mycoplasma contamination by the manufacturer, and additional testing for mycoplasma contamination was not
performed. All cell lines were maintained in DMEM GlutaMAX supplemented with 10% FBS and antibiotic-antimycotic (Thermo Fisher
Scientific; catalogue number: 15240062). Plasmids were transfected
immediately after cell seeding using FuGENE 6 (Promega, Madison,
WI; catalogue number: E2691). In some cases, actin was labeled
using SiR-actin (Cytoskeleton, Denver, CO; catalogue number: CYSC001) by incubating COS-7 cells 12 h after seeding with 10 μM
verapamil (Cytoskeleton catalogue number: CY-SC001) and 1 μM
SiR-actin. When indicated, cells were serum-starved by incubation for
2 h in growth medium lacking FBS. For pharmacological activation of
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AMPK, HEK293T cells expressing IRSp53-FLAG were pretreated with
the CaMKK2 inhibitor STO-609 (Santa Cruz Biotechnology; catalogue number: sc-202820) for 1 h before replacing the culture media
with fresh media that include the indicated concentrations of the
AMPK activator phenformin hydrochloride (Santa Cruz Biotechnology; catalogue number: sc-219590) for 1 h before lysis. AMPK was
inhibited by incubating IRSp53-FLAG-expressing cells in cell culture
media (with or without 10% FBS) supplemented with the indicated
concentrations of dorsomorphin dihydrochloride (Santa Cruz Biotechnology; catalogue number: sc-361173) for 2 h. In some of the
experiments (as indicated), serum-starved cells were additionally
treated with 0.1 μM insulin (Santa Cruz Biotechnology; catalogue
number: sc-360248) for 10 min before imaging or lysis.

Live cell imaging
All cells were imaged 18–24 h posttransfection using either an
Olympus IX81 inverted microscope equipped with a 100× (1.4 NA)
Plan-Apo oil immersion objective and a Yokogawa spinning disk
confocal attached to an Andor iXon3 EMCCD camera (Figures 1–5
and Supplemental Figure S4, C and D) or a Nikon Ti2 inverted
microscope equipped with a 100× (1.4 NA) Plan-Apo oil immersion
objective and a Yokogawa CSU-W1 spinning disk confocal attached
to a Hamamatsu ORCA-FLASH4.0 CMOS camera (Supplemental
Figures S1B and S4B). Cells in DMEM FluoroBrite (Thermo Fisher
Scientific; catalogue number: A1896701) medium supplemented
with 0.5% FBS were imaged at 37°C and 5% CO2. Images were
captured at 2- or 5-s intervals for 5 min at 14-bit resolution using the
Metamorph software (Molecular Devices, San Jose, CA). The analysis of videos and images, including measurements of cell protrusion
density, length, and growth rate, was performed with the software
Fiji (National Institutes of Health [NIH]).

Phosphoproteomics
Coomassie Blue-stained gels were cut into 1 × 1-mm pieces, destained with 50% methanol and 1.25% acetic acid, reduced with
5 mM dithiothreitol (DTT), and alkylated with 20 mM iodoacetamide. The pieces were then washed with 20 mM ammonium bicarbonate and dehydrated with acetonitrile. Proteins were proteolyzed
overnight at 37°C with the addition of 5 ng ml–1 trypsin in 20 mM
ammonium bicarbonate. Peptides were extracted with 0.3% trifluoroacetic acid, followed by a 50% acetonitrile/water solution. Tryptic
peptides were separated by reverse-phase high-performance liquid
chromatography using a 75 μm i.d. × 25 cm Acclaim PepMap nano
LC column and eluted peptides were analyzed by LC-MS/MS on a
Q Exactive HF mass spectrometer (Thermo Fisher Scientific). The
mass spectrometer was set to repetitively scan the mass-to-charge
ratio in the range 300–1400 (resolution of 240,000), followed by
data-dependent MS/MS scans (resolution of 15,000) on the 20 most
abundant ions, with a minimum automatic gain control (AGC) target
of 1e4. Dynamic exclusion was enabled with a repeat count of 1 and
a repeat duration of 30 s. The Fourier transform mass spectrometry
full scan AGC target value was set to 3e6, while MSn AGC was 1e5.
The MSn injection time was set to 160 ms, and microscans were not
averaged. FT preview mode charge state screening and monoisotopic precursor selection were all enabled, with rejection of unassigned and 1+ charge states.
Database searching was performed using the Proteome Discoverer software v1.4 (Thermo Fisher Scientific) and against the UniProt
human database appended with common contaminants using the
SEQUEST algorithm. SEQUEST was searched with a fragment ion
mass tolerance of 0.020 Da and a parent ion tolerance of 10.0 PPM.
Carbamidomethyl of cysteine was specified as a fixed modification.
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Methionine oxidation, N-terminal acetylation, and serine phosphorylation were specified as variable modifications. The program Scaffold v4.6.1 (Proteome Software, Portland, OR) was used to validate
MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than
95.0% probability by the Scaffold Local FDR algorithm, whereas
protein identifications were accepted if they could be established at
greater than 95.0% probability and contained at least one identified
peptide. Protein probabilities were assigned by the Protein Prophet
algorithm (Nesvizhskii et al., 2003). Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony. Proteins
sharing significant peptide evidence were grouped into clusters.
The localization of the phosphorylation sites was validated using the
Ascore algorithm (Beausoleil et al., 2006) in Scaffold PTM v3.2.0. All
identified peptides, posttranslational modifications, and peptides
are reported in Supplemental Tables 1 and 2.

Chemotaxis
Cell migration analysis was performed using an IncuCyte ClearView
96-Well Chemotaxis Plate System (Essen BioScience) by tracking the
migration of HT-1080 cells from a 96-well upper plate to a lower
plate containing the chemoattractant (FBS). The upper plate was
coated with 10 μg ml–1 fibronectin and seeded with ∼2000 cells. Cells
were either untransfected or transiently transfected with constructs
IRSp53-GFP, M234-GFP, RFP-Cdc42, and/or mCherry-14-3-3, as indicated (Figure 5). Cells in the upper plate were incubated for 3 h in
DMEM (Thermo Fisher Scientific) supplemented with 0.5% FBS to
allow for their attachment before loading the lower plate containing
DMEM supplemented with 0.5–20% FBS. Chemotaxis plates were
calibrated for parameters that could affect migration time, including
fibronectin coating, chemoattractant concentration, and imaging
delay, by determining the time where the maximum number of untransfected cells had migrated from the top plate to the bottom
plate. A total of six bright field green and red fluorescence images
were collected per well (top and bottom) every 2 h and for a period
of 63 h. Images were analyzed using the IncuCyte Chemotaxis Software (Essen BioScience) using either bright field images for untransfected cells or green and red fluorescence images for transfected
cells. Each experimental condition was repeated at least four times.

Quantification and statistical analysis
Filopodia statistics. Live cell images were sampled randomly for
FLS analysis. Randomly motorized stage coordinates (x and y),
within the viewable area of the 35-mm FluoroDish (World Precision
Instruments, Sarasota, FL; catalogue number: FD35), were generated
and used in the automated image collection macro of the program
MetaMorph (Molecular Devices) designed to move the stage, focus,
and perform image recordings. Nonoverlapping FLS, defined as
dynamic, nontapered protrusions 0.2–0.5 μm in width and extending
at least 0.5 μm from the cell periphery, were measured manually
using the program Fiji (NIH) in images containing attached,
nonblebbing and nondividing cells. FLS density was determined as
the ratio between the number of FLS and the total perimeter of the
cell. FLS length was determined by measuring the maximum length
of dynamic protrusions observed over at least 5 min of an image
sequence. FLS length was measured in the green (or blue) channel
for cells expressing IRSp53-GFP (or IRSp53-mTagBFP2) or M234GFP. For cells expressing only RFP-Cdc42, mCherry-VASP, mCherryEps8, mTAGBFP2-14-3-3θ, or cells treated with SiR-actin, FLS were
quantified using the respective emission channels. These proteins
are typically found along the length of FLS (Jacquemet et al., 2019),
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and measuring FLS lengths in these channels has a negligible effect
(<10%) on the length distribution of FLS. FLS growth rate was
determined as the maximum extension speed of a FLS growing
uninterruptedly for 30 s or more. FLS growth rate was not measured
for static FLS or for FLS that moved out of the field of view within
30 s. Statistical analysis was performed on the aggregated number
of observations.
Statistical methods. The data are presented as the mean ± SD. The
statistical significance of the measurements was determined, using
the program Prism 7c (GraphPad Software, La Jolla, CA), using either the unpaired two-sided Student’s t test or Mann–Whitney’s rank
sum test (as indicated). A p value ≤ 0.05 was considered significant.
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